Stevanato Group S.p.A. Profile Avatar - Palmy Investing

Stevanato Group S.p.A.

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for pharma and healthcare. Its principal products include containment solutions, drug delivery systems, medical devices, …
Medical - Instruments & Supplies
IT, Piombino Dese [HQ]
Financials

Analysts

Earnings
Reported
Past Estimate Consensus
Future Estimate Consensus
EPS Revenue EBITDA EBIT SGA
FY EPS Revenue [mil.] Profit [mil.] EBITDA [mil.] EBIT [mil.] Expenses · SGA [mil.]
E E E E E E
All monetary values are presented in USD ($). E stands for Estimate.
2021 - 0.524 - 945 - 138 - 213 - 143 - 107
2022 0.5300 0.565 843 1,031 134 149 184 232 162 156 82 117
2023 0.5300 0.655 983 1,191 142 173 217 268 192 181 111 136
2024 0.5400 0.524 1,063 1,190 145 138 263 268 186 181 102 135
2025 - 0.612 - 1,279 - 148 - 288 - 194 - 145
2026 - 0.784 - 1,455 - 1.F5X/td> - 1.F51/td> - 1.F51 - 1.F51
2027 - 1.001 - 1,736 - 0.F6X/td> - 0.F61/td> - 0.F61 - 0.F61
Institutional Sentiment
Morgan Stanley
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
JP Morgan Chase
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Citigroup
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Overall Consensus
Grading Consensus
Click to each, to see the grade
Price Target Consensus

-33.806% $6.67 · MISS

Nov. 6, 2024
Price Then
$22.50
Price Target
$26.40
Price Now
$19.73
End of STVN's Analysis
CIK: 1849853 CUSIP: T9224W109 ISIN: IT0005452658 LEI: - UEI: -
Secondary Listings
STVN has no secondary listings inside our databases.